Skip to content
Menu

Celldex Therapeutics, Inc. CLDX

Full chart Compare
Set alert

Price alert · CLDX

All alert types
27.42 USD -0.54 (-1.93%)

Regular-session close

27.40 -0.02 -0.07%

After hours · Nov 20, 5:33 PM ET

26.64 Day range 28.43
22.58 52-week range 44.87
YTD
+0.96%
1 year
+9.37%

5D -0.29 (-1.03%)

27.502828.5029FriMonTueWedThu27.96
Market cap
2.15B
Revenue (ttm)
158.00K
EPS (ttm)
-4.29
Shares out
78.55M
Forward P/E
-6.57
YTD return
+0.96%
1-year return
+9.37%
50-day average
31.11
200-day average
32.91
Enterprise value
1.56B
Volume
1.72M
Avg volume
1.32M
Open
27.05
Previous close
27.96
Day's range
26.64 – 28.43
52-week range
22.58 – 44.87
Beta
1.03
Analysts
Strong Buy
Price target
63.79 (+132.6%)
Earnings date
Feb 24, 2027

Key statistics

Price / sales
13631.05
Price / book
3.32
Free cash flow
-154.39M
Total cash
650.32M
Total debt
9.87M
Return on equity
-49.54%
Short % of float
15.01%

Fundamental scorecard

4 of 25 checks passed on CLDX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CLDX Revenue — quarterly 0
CLDX Net income — quarterly -75.56M
CLDX EPS — quarterly -0.96

Earnings

CLDX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-1.05———
Nov 5, 2026Sep 30, 2026-1.02-0.96+0.06+5.88%
Aug 6, 2026Jun 30, 2026-1.06-0.94+0.12+11.32%
May 7, 2026Mar 31, 2026-1.15-1.18-0.03-2.86%
Feb 25, 2026Dec 31, 2025-1.00-1.22-0.22-22.00%
Nov 10, 2025Sep 30, 2025-0.88-1.01-0.13-14.77%

Upgrades / downgrades

CLDX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2026BarclaysmainOverweightOverweight
Nov 20, 2026HC Wainwright & Co.mainBuyBuy
Nov 9, 2026Canaccord GenuitymainBuyBuy
Nov 9, 2026Morgan StanleymainOverweightOverweight
Oct 2, 2026HC Wainwright & Co.reitBuyBuy
Sep 23, 2026Leerink PartnersmainOutperformOutperform

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
celldex.com

News

Your note

Sign in to keep a note on CLDX — it syncs with the Stock Master app.

Insider holders

CLDX insider holders
InsiderRelationLatest transactionDateShares held
JIMENEZ FREDDY AGeneral CounselSaleDec 3, 202530,796
MARTIN SAMUEL BATESChief Financial OfficerConversion of Exercise of derivative securityJan 1, 202632,942
PEPIN RONALD AOfficerConversion of Exercise of derivative securityDec 14, 202520,097
WRIGHT RICHARD MFormerConversion of Exercise of derivative securityNov 12, 202520,833

Institution ownership

CLDX institution ownership
Holder% heldSharesValueReported
Wellington Management Group, LLP13.58%10,671,399292.61MSep 29, 2026
FMR, LLC10.99%8,637,498236.84MSep 29, 2026
Blackrock Inc.8.84%6,948,371190.52MSep 29, 2026
Kynam Capital Management, LP6.45%5,066,051138.91MSep 29, 2026
Price (T.Rowe) Associates Inc5.58%4,385,929120.26MSep 29, 2026
State Street Corporation4.43%3,478,54995.38MSep 29, 2026

Fund ownership

CLDX fund ownership
Holder% heldSharesValueReported
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund4.82%3,783,994103.76MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%2,487,75868.21MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.57%2,020,86955.41MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.04%1,603,13843.96MSep 29, 2026
Vanguard Explorer Fund1.84%1,447,60839.69MJul 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.60%1,254,60334.40MJun 29, 2026